Andreas Geier

researcher

Andreas Geier is …
instance of (P31):
humanQ5

External links are
P496ORCID iD0000-0002-9626-5083

P734family nameGeierQ21509304
GeierQ21509304
GeierQ21509304
P735given nameAndreasQ4926263
AndreasQ4926263
P106occupationresearcherQ1650915
P21sex or gendermaleQ6581097

Reverse relations

author (P50)
Q90697684A 2-step fast-track elastometry service for advanced workup of nonalcoholic fatty liver disease (NAFLD) patients - single-center real-world experience of outpatient clinical practice
Q53298107A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease.
Q45140568Adaptation of iron transport and metabolism to acute high-altitude hypoxia in mountaineers
Q38737633Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease
Q61218108Combined effect of 25-OH vitamin D plasma levels and genetic Vitamin DReceptor (NR 1I1) variants on fibrosis progression rate in HCV patients
Q87889291Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers
Q81424742Cytokine-independent repression of rodent Ntcp in obstructive cholestasis
Q114615576Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
Q42269830Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients
Q38748157Emerging therapies for NASH - the future is now.
Q90697300Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis
Q36482742Host genetic variants in the pathogenesis of hepatitis C.
Q44487750Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection
Q94588841Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Non-carriers
Q36606886Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis.
Q92521100Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness
Q113859042NAFLD patients scheduled for bariatric surgery present with a milder disease phenotype as compared to not morbidly obese NAFLD patients: analysis of a large real-world cohort
Q64121032Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective
Q90710997Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts?
Q45043485Reply to: "estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?".
Q46588775Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver
Q44749286Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis.
Q34251524The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients

Search more.